Israel Embassy blast case: Accused used crude bomb with home-made timer, post-blast analysis finds ‘chemical explosion’ Days after the blast at the Israel Embassy, probe by Delhi Police said that the accused used a crude bomb with a “homemade” timer to set it off, reports The Indian Express, citing Delhi Police sources. A post-blast analysis report from the National Security Guard (NSG) also showed that it was a chemical explosion that had ball bearings, metal pellets, nails and metal pieces. The blast occurred in the area between the boundary walls of the house on plot number 4 – Nanda’s House – and the Central Hindi Training Institute on plot 2A on Prithviraj Road on December 26. Police said that it received a call about a “loud thud” heard behind the Embassy. No one was injured in the bast. Police had said that they recovered shrapnel, ball bearings and an “abusive” letter that was addressed to the Israel Embassy ambassador, which was allegedly sent by a group called “Sir Allah Resistance”. The letter and its envelope were sent to the Forensic Science Laboratory, and other parts of the IED were sent for further analysis. Police are yet to arrest the suspect. The Delhi Police’ Special Cell said that multiple teams have been working on the case. Three days after the blast, Delhi Police had registered an FIR against unknown persons under Section 3 of the Explosive Substances Act (punishment for causing an explosion likely to endanger life or property) at Tughlak Road police station based on a complaint by a cop. Similar threats were received by the Israel Embassy two months before the actual blast, the Indian Express had earlier reported. The threats were sent online and addressed to the Israel Embassy ambassador. The accused talked about the war in Gaza.
BDENZA ORAL SOLUTION represents a significant advancement in prostate cancer therapy, offering relief and hope to millions of patients worldwide.
“BDENZA represents a paradigm shift in prostate cancer therapy. Its introduction aligns with our relentless pursuit to provide accessible and patient-centric healthcare solutions. This first-of-its-kind oral solution that addresses the challenges faced by many patients, offering convenience, reduced side effects, and a palatable sugar-free taste and affordability,” Raheel Shah, BDR Group Director (Business Development) said in a statement.
BDENZA ORAL SOLUTION represents a significant advancement in prostate cancer therapy, offering relief and hope to millions of patients worldwide.
“BDENZA represents a paradigm shift in prostate cancer therapy. Its introduction aligns with our relentless pursuit to provide accessible and patient-centric healthcare solutions. This first-of-its-kind oral solution that addresses the challenges faced by many patients, offering convenience, reduced side effects, and a palatable sugar-free taste and affordability,” Raheel Shah, BDR Group Director (Business Development) said in a statement.
Kotak Mahindra Capital Company Ltd, ICICI Securities Ltd and JP Morgan India Pvt Ltd are the book running lead managers to the issue.
The equity shares of Blue Jet Healthcare are proposed to be listed on the BSE and the NSE.